Platelet glycoprotein proteolysis: novel mechanisms and risk factors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1147214

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Platelets are the richest source of amyloid precursor protein (APP) in the body. Platelet ADAM10 regulates both the expression and function of the major platelet collagen receptor GPVI, and protective APP processing. Coagulation protein Factor X has a role in activation of ADAM10. This activation is disrupted in blood that has been treated with direct oral anticoagulant (DOAC) rivaroxaban. This grant will investigate the implications for people taking rivaroxaban on regulation of APP and GPVI.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $441,473.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Receptors and Membrane Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

amyloid precursor protein | anticoagulants | coagulation protein | metalloproteinase | platelets

Related Links